Skip to main content

Advertisement

SpringerLink
Log in

Biomarkers of atherosclerosis: Clinical applications

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Current cardiovascular risk prediction models incorporate traditional risk factors to estimate 10-year cardiovascular risk. Numerous blood-based biomarkers have been identified that are associated with increased cardiovascular risk after adjusting for traditional risk factors. Many of these biomarkers, alone or in combination, have been incorporated into risk prediction models to determine whether their addition increases the model’s predictive ability. We review the recently published literature on blood-based biomarkers and examine whether incorporating these markers may improve clinical decision making.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Wilson PW, D’Agostino RB, Levy D, et al.: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837–1847.

    PubMed  CAS  Google Scholar 

  2. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486–2497.

  3. Lloyd-Jones DM, Leip EP, Larson MG, et al.: Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006, 113:791–798.

    Article  PubMed  Google Scholar 

  4. Ware JH: The limitations of risk factors as prognostic tools. N Engl J Med 2006, 355:2615–2617.

    Article  PubMed  CAS  Google Scholar 

  5. Cook NR: Use and misuse of the receiver operator characteristic curve in risk prediction. Circulation 2007, 115:928–935.

    Article  PubMed  Google Scholar 

  6. Brunzell JD, Davidson M, Furberg CD, et al.: Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008, 51:1512–1524.

    Article  PubMed  Google Scholar 

  7. Sacks FM: The apolipoprotein story. Atheroscler Suppl 2006, 7:23–727.

    Article  PubMed  CAS  Google Scholar 

  8. Barter PJ, Ballantyne CM, Carmena R, et al.: Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty person/ten country panel. J Intern Med 2006, 259:247–258.

    Article  PubMed  CAS  Google Scholar 

  9. Frontini MG, Srinivasan SR, Xu J, et al.: Usefulness of childhood non high density lipoprotein cholesterol levels versus other lipoprotein measures in predicting adult subclinical atherosclerosis: the Bogalusa Heart Study. Pediatrics 2008, 121:924–929.

    Article  PubMed  Google Scholar 

  10. Ingelsson E, Schaefer EJ, Contois JH, et al.: Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007, 298:776–785.

    Article  PubMed  CAS  Google Scholar 

  11. van der Steeg WA, Boekholdt SM, Stein EA, et al.: Role of the apolipoprotein B-apolipoprotein A-1 ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 2007, 146:640–648.

    PubMed  Google Scholar 

  12. Virani SS, Polsani VR, Nambi V: Novel markers of inflammation in atherosclerosis. Curr Atheroscler Rep 2008, 10:164–170.

    Article  PubMed  CAS  Google Scholar 

  13. Nambi V: The use of myeloperoxidase as a risk marker for atherosclerosis. Curr Atheroscler Rep 2005, 7:127–131.

    Article  PubMed  CAS  Google Scholar 

  14. Meuwese MC, Stroes ES, Hazen SL, et al.: Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population study. J Am Coll Cardiol 2007, 50:159–165.

    Article  PubMed  CAS  Google Scholar 

  15. Garza CA, Montori VM, McConnell JP, et al.: Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007, 82:159–165.

    Article  PubMed  CAS  Google Scholar 

  16. Ballantyne CM, Hoogeveen RC, Bang H, et al.: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005, 165:2479–2484.

    Article  PubMed  CAS  Google Scholar 

  17. Ridker PM: C-reactive protein and the prediction of cardiovascular events among those at intermediate risk. J Am Coll Cardiol 2007, 49:2129–2138.

    Article  PubMed  CAS  Google Scholar 

  18. Sabatine MS, Morrow DA, Jablonski KA, et al.: Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007, 115:1528–1536.

    Article  PubMed  Google Scholar 

  19. Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499–511.

    Article  PubMed  Google Scholar 

  20. Vidula H, Tian L, Liu K, et al.: Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann Intern Med 2008, 148:85–93.

    PubMed  Google Scholar 

  21. Cook NR, Buring JE, Ridker PM: The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006, 145:21–29.

    PubMed  CAS  Google Scholar 

  22. Ridker PM, Buring JE, Rifai N, Cook NR: Development and validation of improved algorithms for the assessment of global cardiovascular risk in women. JAMA 2007, 297:611–619.

    Article  PubMed  CAS  Google Scholar 

  23. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. Fibrinogen Studies Collaboration [no authors listed]. JAMA 2005, 294:1799–1809.

  24. Jenny NS, Yanez ND, Psaty BM, et al.: Inflammation biomarkers and near-term death in older men. Am J Epidemiol 2007, 165:684–695.

    Article  PubMed  Google Scholar 

  25. Zakai NA, Katz R, Jenny NS, et al.: Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. J Thromb Haemost 2007, 5:1128–1135.

    Article  PubMed  CAS  Google Scholar 

  26. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal definition of myocardial infarction. J Am Coll Cardiol 2007, 50:2173–2195.

    Article  PubMed  Google Scholar 

  27. Antman EM, Anbe DT, Armstrong PW, et al.: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 2004. Available at http://www.acc.org/qualityandscience/clinical/guidelines/stemi/STEMI%20Full%20Text.pdf. Accessed August 15, 2008.

  28. Anderson JL, Adams CD, Antman EM, et al.: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College of Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007, 50:e1–e157.

    Article  PubMed  Google Scholar 

  29. Schulz O, Paul-Walter C, Lehmann M, et al.: Usefulness of detectable levels of troponin, below the 99th percentile of the normal range, as a clue to the presence of underlying coronary artery disease. Am J Cardiol 2007, 100:764–769.

    Article  PubMed  CAS  Google Scholar 

  30. Agewall S, Olsson T, Lowbeer C: Usefulness of troponin levels below the diagnostic cut-off level for acute myocardial infarction predicting prognosis in unselected patients admitted to the coronary care unit. Am J Cardiol 2007, 99:1357–1359.

    Article  PubMed  CAS  Google Scholar 

  31. Zethelius B, Johnston N, Venge P: Troponin I as a predictor of coronary heart disease and mortality in 70-year old men: a community-based cohort. Circulation 2006, 113:1071–1078.

    Article  PubMed  CAS  Google Scholar 

  32. de Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet 2003, 362:316–322.

    Article  PubMed  CAS  Google Scholar 

  33. Omland T, de Lemos JA: Amino-terminal pro-B-type natriuretic peptides in stable and unstable ischemic heart disease. Am J Cardiol 2008, 101(Suppl):61A–66A.

    Article  CAS  Google Scholar 

  34. Khan SQ, Quinn P, Davies JE, Ng LL: N-terminal pro-Btype natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction. Heart 2008, 94:40–43.

    Article  PubMed  CAS  Google Scholar 

  35. Weber M, Bazzino O, Navarro Estrada JL, et al.: Nterminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission. J Am Coll Cardiol 2008, 51:1188–1195.

    Article  PubMed  CAS  Google Scholar 

  36. Windhausen F, Hirsch A, Sanders GT, et al.: N-terminal pro-brain natriuretic peptide for additional risk stratification in patients with non-ST-elevation acute coronary syndrome and an elevated troponin T: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. Am Heart J 2007, 153:485–492.

    Article  PubMed  CAS  Google Scholar 

  37. Bibbins-Domingo K, Gupta R, Na B, et al.: N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 2007, 297:169–176.

    Article  PubMed  CAS  Google Scholar 

  38. Omland T, Sabatine MS, Jablonski KA, et al.: Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease. J Am Coll Cardiol 2007, 50: 205–214.

    Article  PubMed  CAS  Google Scholar 

  39. N-terminal pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF Heart Protection Study. Heart Protection Study Collaborative Group [no authors listed]. J Am Coll Cardiol 2007, 49:311–319.

  40. Olsen MH, Hansen TW, Christensen MK, et al.: N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 2007, 28:1374–1381.

    Article  PubMed  CAS  Google Scholar 

  41. Ix JH, Shlipak MG, Chertow GM, Whooley MA: Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul study. Circulation 2007, 115:173–179.

    Article  PubMed  CAS  Google Scholar 

  42. Maahs DM, Ogden LG, Kretowski A, et al.: Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. Diabetes 2007, 56:2774–2779.

    Article  PubMed  CAS  Google Scholar 

  43. Blankenberg S, McQueen MJ, Smieja M, et al.: Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2006, 114: 201–208.

    Article  PubMed  CAS  Google Scholar 

  44. Wang TJ, Gona P, Larson MG, et al.: Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006, 355:2631–2639.

    Article  PubMed  CAS  Google Scholar 

  45. Shlipak MG, Ix JH, Bibbins-Domingo K, et al.: Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul study. Am J Med 2008, 121:50–57.

    Article  PubMed  CAS  Google Scholar 

  46. Zethelius B, Berglund L, Sundstrom J, et al.: Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358:2107–2116.

    Article  PubMed  CAS  Google Scholar 

  47. de Lemos JA, Lloyd-Jones DM: Multiple biomarker panels for cardiovascular risk assessment. N Engl J Med 2008, 358:2172–2174.

    Article  PubMed  Google Scholar 

  48. Ridker PM; JUPITER Study Group: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003, 108:2292–2297.

    Article  PubMed  Google Scholar 

  49. Ridker PM, Fonseca FA, Genest J, et al.: Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 2007, 100:1659–1664.

    Article  PubMed  Google Scholar 

  50. JUPITER halted: rosuvastatin significantly reduces cardiovascular morbidity and mortality. Available at http://www.theheart.org/article/852735.do. Accessed August 15, 2008.

Download references

Author information

Authors and Affiliations

  1. Preventive Cardiology, University of Alabama at Birmingham, Division of Cardiovascular Disease, 701 19th Street South - LHRB 310, Birmingham, AL, 35294-0007, USA

    Vera Bittner

Authors
  1. Todd M. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vera Bittner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vera Bittner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brown, T.M., Bittner, V. Biomarkers of atherosclerosis: Clinical applications. Curr Cardiol Rep 10, 497–504 (2008). https://doi.org/10.1007/s11886-008-0078-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-008-0078-1

Keywords

Search

Navigation